PE20110119A1 - Asociacion entre ferroquina y artesunato para el tratamiento del paludismo - Google Patents

Asociacion entre ferroquina y artesunato para el tratamiento del paludismo

Info

Publication number
PE20110119A1
PE20110119A1 PE2010000537A PE2010000537A PE20110119A1 PE 20110119 A1 PE20110119 A1 PE 20110119A1 PE 2010000537 A PE2010000537 A PE 2010000537A PE 2010000537 A PE2010000537 A PE 2010000537A PE 20110119 A1 PE20110119 A1 PE 20110119A1
Authority
PE
Peru
Prior art keywords
artesunato
malaria
treatment
ferroquina
association
Prior art date
Application number
PE2010000537A
Other languages
English (en)
Inventor
Laurent Fraisse
Daniel Ter-Minassian
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20110119A1 publication Critical patent/PE20110119A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: A) FERROQUINA EN FORMA DE BASE LIBRE O SAL; B) ARTESUNATO O ARTEMETER. C) EXCIPIENTES TALES COMO GELATINA, ALMIDON, LACTOSA, ENTRE OTROS. DICHA COMPOSICION SE PUEDE ENCONTRAR COMO COMPRIMIDOS, CAPSULAS, POLVOS, ENTRE OTROS. TAMBIEN REFIERE A UN METODO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL PALUDISMO
PE2010000537A 2005-04-20 2006-04-17 Asociacion entre ferroquina y artesunato para el tratamiento del paludismo PE20110119A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503932A FR2884715B1 (fr) 2005-04-20 2005-04-20 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Publications (1)

Publication Number Publication Date
PE20110119A1 true PE20110119A1 (es) 2011-03-08

Family

ID=35385843

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000399A PE20061314A1 (es) 2005-04-20 2006-04-17 Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
PE2010000537A PE20110119A1 (es) 2005-04-20 2006-04-17 Asociacion entre ferroquina y artesunato para el tratamiento del paludismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000399A PE20061314A1 (es) 2005-04-20 2006-04-17 Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo

Country Status (30)

Country Link
US (1) US20120258945A1 (es)
EP (1) EP1874293A1 (es)
JP (1) JP5148478B2 (es)
KR (1) KR20080009088A (es)
CN (2) CN102836163A (es)
AP (1) AP2782A (es)
AR (1) AR054253A1 (es)
AU (1) AU2006238506B2 (es)
BR (1) BRPI0610851A2 (es)
CA (1) CA2605385A1 (es)
CR (1) CR9425A (es)
DO (1) DOP2006000092A (es)
EA (1) EA012630B1 (es)
FR (1) FR2884715B1 (es)
GT (1) GT200600157A (es)
HN (1) HN2006015130A (es)
IL (1) IL186048A0 (es)
MA (1) MA29451B1 (es)
MX (1) MX2007012645A (es)
MY (1) MY145581A (es)
NO (1) NO20075920L (es)
NZ (1) NZ562117A (es)
PA (1) PA8669801A1 (es)
PE (2) PE20061314A1 (es)
SG (1) SG161270A1 (es)
TN (1) TNSN07359A1 (es)
TW (1) TWI387456B (es)
UA (1) UA96414C2 (es)
WO (1) WO2006111647A1 (es)
ZA (1) ZA200708800B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926993B1 (fr) 2008-02-06 2011-03-11 Sanofi Aventis Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme
FR2952823B1 (fr) * 2009-10-30 2012-04-20 Sanofi Aventis Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
FR2961209B1 (fr) * 2010-06-11 2013-03-01 Sanofi Aventis Procede de synthese de la ferroquine par amination reductrice convergente.
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
CN105250295B (zh) * 2014-07-07 2018-12-25 广州中医药大学科技产业园有限公司 一种联合用药物及其作为免疫调节剂的应用
US10512652B2 (en) 2015-07-20 2019-12-24 University Of Vermont And State Agricultural College Use of cymanquine compounds as antimalarial agents
CN107802755A (zh) * 2017-11-08 2018-03-16 江西龙卿堂科技有限公司 一种具有防蚊防疟作用的青蒿软膏
KR102073961B1 (ko) * 2018-11-16 2020-02-05 (주)프론트바이오 메트포르민 및 페로센계 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2022231238A1 (ko) * 2021-04-26 2022-11-03 심민보 아르테수네이트 또는 그의 염, 및 피로나리딘 또는 그의 염의 해열, 항염증, 항바이러스용, 또는 covid-19 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
CN113952360B (zh) * 2021-09-14 2023-03-10 上海交通大学 一种亚铁离子在治疗疟疾的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN166154B (es) * 1987-05-08 1990-03-24 Hoechst India
BRPI0413767A (pt) * 2003-09-04 2006-10-31 Cipla Ltd produto farmacêutico ou formulação farmacêutica, processo para preparar um produto farmacêutico ou formulação farmacêutica, método para tratar um doença e uso de pelo menos uma artemisinina ou um sal, solvato ou derivado desta

Also Published As

Publication number Publication date
AP2782A (en) 2013-10-31
MY145581A (en) 2012-02-29
NO20075920L (no) 2007-11-16
EA200702282A1 (ru) 2008-02-28
GT200600157A (es) 2006-11-07
AP2007004211A0 (en) 2007-10-31
TNSN07359A1 (en) 2008-12-31
PE20061314A1 (es) 2006-12-27
AU2006238506A1 (en) 2006-10-26
MX2007012645A (es) 2007-12-13
FR2884715B1 (fr) 2007-06-15
SG161270A1 (en) 2010-05-27
US20120258945A1 (en) 2012-10-11
CR9425A (es) 2008-02-20
KR20080009088A (ko) 2008-01-24
PA8669801A1 (es) 2006-11-09
AU2006238506B2 (en) 2012-03-01
JP2008536900A (ja) 2008-09-11
CN101163470A (zh) 2008-04-16
JP5148478B2 (ja) 2013-02-20
TWI387456B (zh) 2013-03-01
ZA200708800B (en) 2009-01-28
TW200716092A (en) 2007-05-01
WO2006111647A1 (fr) 2006-10-26
EP1874293A1 (fr) 2008-01-09
FR2884715A1 (fr) 2006-10-27
MA29451B1 (fr) 2008-05-02
NZ562117A (en) 2010-01-29
EA012630B1 (ru) 2009-10-30
DOP2006000092A (es) 2006-11-15
AR054253A1 (es) 2007-06-13
BRPI0610851A2 (pt) 2010-08-03
HN2006015130A (es) 2010-08-19
CA2605385A1 (fr) 2006-10-26
UA96414C2 (ru) 2011-11-10
IL186048A0 (en) 2008-02-09
CN102836163A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
PE20110119A1 (es) Asociacion entre ferroquina y artesunato para el tratamiento del paludismo
AR123409A2 (es) Composiciones terapéuticas
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
TW200942524A (en) Novel aminomethyl benzene derivatives
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
DE602008005316D1 (de) Tablettierte atazanavirhaltige zusammensetzungen
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
PE20140255A1 (es) Tableta dispersable en forma oral
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
DE602008005896D1 (de) Tablettierte atazanavirhaltige zusammensetzungen
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2015001615A1 (es) Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades.
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
MY191875A (en) Solid dosage form
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
PE20110943A1 (es) Formulacion oral solida de alisquireno
UY33870A (es) Compuesto para el tratamiento de disfunción cognitiva en esquizofrenia, sus usos y composición que lo contiene
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
DE602008005462D1 (de) Tablettierte atazanavirhaltige zusammensetzungen

Legal Events

Date Code Title Description
FC Refusal